US EditionSenate panel questions Trump nominee to lead National Institutes of Health
- Dr. Jay Bhattacharya, nominated to lead the National Institutes of Health, faces scrutiny due to his past criticisms of COVID-19 policies and the NIH's operations, which some say threaten the future of medical research.
- The NIH, funding nearly $48 billion in research, has faced heavy criticism and staffing losses during the Trump administration, with about 1,200 employees laid off so far.
- Bhattacharya plans to foster a culture of scientific dissent and transparency at the NIH, criticizing it for its previous culture of coverup and lack of tolerance for differing ideas.
- Prominent figures, including Senators Patty Murray and Bill Cassidy, stress the importance of strong leadership at the NIH amid ongoing political challenges.
24 Articles
24 Articles
Trump NIH appointee defends president's research funding cuts, lays out new vision for future
Donald Trump's pick to lead the NIH was peppered with questions from Democrats about the president's cuts to NIH research funding during his confirmation hearing Wednesday.
Trump NIH nominee aims to soothe senators over embattled agency
President Donald Trump’s nominee to lead the National Institutes of Health sought to reassure senators Wednesday that he would bring stability to an agency that has faced mass terminations and frozen funding of health research since Trump took office. Jay Bhattacharya, a Stanford health economist who faced criticism for his suggested approach to the COVID-19 pandemic, told senators he aims to restore trust in public health and science, bring mo…
LIVE NOW: Nomination of Jayanta Bhattacharya as NIH Director: Senate Health Committee Hearing
U.S. Senate Health, Education, Labor, and Pensions Committee holds a hearings to examine the nomination of Jayanta Bhattacharya, of California, to be Director of the National Institutes of Health, Department of Health and Human Services at 10 a.m. ET on Mar. 5. ...
Coverage Details
Bias Distribution
- 38% of the sources lean Left
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
